Exploring disease-specific metabolite signatures in hereditary angioedema patients.


Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2024
Historique:
received: 19 10 2023
accepted: 15 04 2024
medline: 10 5 2024
pubmed: 10 5 2024
entrez: 10 5 2024
Statut: epublish

Résumé

Hereditary angioedema (HAE) is a rare, life-threatening autosomal dominant genetic disorder caused by a deficient and/or dysfunctional C1 esterase inhibitor (C1-INH) (type 1 and type 2) leading to recurrent episodes of edema. This study aims to explore HAE patients' metabolomic profiles and identify novel potential diagnostic biomarkers for HAE. The study also examined distinguishing HAE from idiopathic angioedema (AE). Blood plasma samples from 10 HAE (types 1/2) patients, 15 patients with idiopathic AE, and 20 healthy controls were collected in Latvia and analyzed using LC-MS based targeted metabolomics workflow. T-test and fold change calculation were used to identify metabolites with significant differences between diseases and control groups. ROC analysis was performed to evaluate metabolite based classification model. A total of 33 metabolites were detected and quantified. The results showed that isovalerylcarnitine, cystine, and hydroxyproline were the most significantly altered metabolites between the disease and control groups. Aspartic acid was identified as a significant metabolite that could differentiate between HAE and idiopathic AE. The mathematical combination of metabolites (hydroxyproline * cystine)/(creatinine * isovalerylcarnitine) was identified as the diagnosis signature for HAE. Furthermore, glycine/asparagine ratio could differentiate between HAE and idiopathic AE. Our study identified isovalerylcarnitine, cystine, and hydroxyproline as potential biomarkers for HAE diagnosis. Identifying new biomarkers may offer enhanced prospects for accurate, timely, and economical diagnosis of HAE, as well as tailored treatment selection for optimal patient care.

Identifiants

pubmed: 38726011
doi: 10.3389/fimmu.2024.1324671
pmc: PMC11080650
doi:

Substances chimiques

Biomarkers 0
Complement C1 Inhibitor Protein 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1324671

Informations de copyright

Copyright © 2024 Kanepa, Fan, Rots, Vaska, Ansone, Briviba, Klovins, Kurjane and Klavins.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Auteurs

Adine Kanepa (A)

Riga Stradiņš University, Riga, Latvia.

Jingzhi Fan (J)

Institute of Biomaterials and Bioengineering, Faculty of Natural Sciences and Technology, Riga Technical University, Riga, Latvia.
Baltic Biomaterials Centre of Excellence, Headquarters at Riga Technical University, Riga, Latvia.

Dmitrijs Rots (D)

Riga Stradiņš University, Riga, Latvia.
Children's Clinical University Hospital, Riga, Latvia.

Annija Vaska (A)

Institute of Biomaterials and Bioengineering, Faculty of Natural Sciences and Technology, Riga Technical University, Riga, Latvia.

Laura Ansone (L)

Latvian Biomedical Research and Study Centre, Riga, Latvia.

Monta Briviba (M)

Latvian Biomedical Research and Study Centre, Riga, Latvia.

Janis Klovins (J)

Latvian Biomedical Research and Study Centre, Riga, Latvia.

Natalja Kurjane (N)

Riga Stradiņš University, Riga, Latvia.
Pauls Stradiņš Clinical University Hospital, Riga, Latvia.

Kristaps Klavins (K)

Institute of Biomaterials and Bioengineering, Faculty of Natural Sciences and Technology, Riga Technical University, Riga, Latvia.
Baltic Biomaterials Centre of Excellence, Headquarters at Riga Technical University, Riga, Latvia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH